Accessible diagnostics for inaccessible populations
Introducing ChipCare’s Polyvalent Analyzer (PAx)
Nucleic acid tests, multiplexed immunoassays, and cell analysis on a fully mobile device at a fraction of the cost.
Without diagnostics, medicine is blind. However, members of key populations and people living in remote areas face significant barriers accessing diagnostics tests.
Bringing these tests to the point-of-care is essential to ending infectious disease epidemics. PAx’s unique combination of mobility, affordability, and the ability to perform three classes of tests make it the only point-of-care device capable of bringing diagnostic testing to inaccessible populations.
PAx will reduce healthcare costs and save lives.
ChipCare’s PAx Platform
3 classes of tests on 1 platform
PAx miniaturizes proven, well-characterized and robust flow cytometer and bead array assay technologies into one mobile device.
PAx is the only point-of-care platform with the ability to perform nucleic acid tests, multiplexed immunoassays, or cell analysis.
PAx uses low-cost, disposable microfluidic cartridges and enables lower capital expenditure by combining multiple devices into one.
PAx is ruggedized, weighs under 2 kilograms, and is designed for use in mobile health settings.
ChipCare’s initial assays support the 90-90-90 targets to end HIV as a global health emergency. Subsequent assays will diagnose other infectious diseases that kill millions, like hepatitis C.
Although ChipCare’s initial focus is on low- and middle-income countries, PAx’s ability to conduct tests typically performed in labs creates the opportunity to dramatically expand the menu of tests available at the point-of-care.
ChipCare’s team of highly experienced professionals from in vitro diagnostics, manufacturing, quality management, and business development are working together to create a platform that will bring accessible diagnostics to inaccessible populations and save lives.
101 College Street, Suite 300
647 255 1378